Understanding HPV tests and their appropriate applications

Cytopathology

Volumn 24, Issue 5, 2013, Pages 289-308

  Cubie, H A ^a   Cuschieri, K ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Cervical screening; Clinically approved validated; Human papillomavirus tests; Human papillomavirus vaccine; Molecular technologies; Oropharyngeal cancer management

Indexed keywords

PROTEIN E7; SURVIVIN;

ANTIBODY RESPONSE; ARTICLE; CANCER REGISTRY; CELL PROLIFERATION; CONFORMATION; CROSS PROTECTION; CROSS REACTION; DISEASE CONTROL; DISEASE COURSE; DNA SCREENING; DYSKARYOSIS; ECOLOGICAL NICHE; ENHANCER REGION; FALSE NEGATIVE RESULT; FOLLOW UP; GENE CONTROL; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; INCIDENCE; META ANALYSIS (TOPIC); NONHUMAN; NUCLEIC ACID AMPLIFICATION; OROPHARYNX CANCER; PATIENT CARE; PATIENT REFERRAL; PENIS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; QUALITY CONTROL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TASK PERFORMANCE; UNCERTAINTY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS; WART VIRUS TEST;

CERVICAL SCREENING; CLINICALLY APPROVED/VALIDATED; HUMAN PAPILLOMAVIRUS TESTS; HUMAN PAPILLOMAVIRUS VACCINE; MOLECULAR TECHNOLOGIES; OROPHARYNGEAL CANCER MANAGEMENT;

CYTODIAGNOSIS; FEMALE; HUMANS; MASS SCREENING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84884700307     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12083     Document Type: Article

References (144)

1. Zur Hausen H. Papillomaviruses in the causation of human cancer - a brief historical account. Virology 2009;384:260-5.
2. Bernard HU, Burk RD, Chen Z et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9.
3. Bouvard V, Baan R, Straif K et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009;10:321-2.
4. Li N, Franceschi S, Howell-Jones R et al. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
5. Cubie HA. When is an STD not an STD? - HPV and cervical cancer. Microbiol Today 2003;30:58-60.
6. Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies of HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
7. Stanley M. HPV-immune response to infection and vaccination. Infect Agent Cancer 2010;20:5-19.
8. Ungar E, Budgeon LR, Myerson D et al. Viral diagnosis by in situ hybridisation. Am J Surg Pathol 1986;10:1-8.
9. Cubie HA, Norval M. Detection of human papillomaviruses in paraffin wax sections with biotinylated synthetic oligonucleotide probes and immunogold staining. J Clin Pathol 1989;42:988-91.
10. Hesselink AT, van den Brule AJ, Brink AA et al. Comparison of hybrid capture 2 with in situ hybridisation for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer 2004;102:11-8.
11. US Food and Drug Administration (FDA). Digene hybrid capture 2 high-risk HPV DNA test - P890064 S009 A004. Available at: http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/recently-approveddevices/ucm082556.htm (Accessed 28 January 2013).
12. College of American Pathologists. Human papillomavirus DNA testing (HPV). Available at: http://www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=%2Fportlets%2FcontentViewer%2Fshow&cntvwrPtlt%7BactionForm.contentReference%7D=committees%2Ftechnology%2FHPV.html&_pageLabel=cntvwr (Accessed 28 January 2013).
13. Castle P, Solomon D, Wheeler CM et al. Human papillomavirus genotype specificity of Hybrid capture 2. J Clin Microbiol 2008;46:2595-604.
14. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010;8:1139-62.
15. Cuschieri K. Human papillomavirus testing: the challenges of picking the right tools for the job. Expert Rev Obstet Gynecol 2011;6:643-53.
16. Guo M, Gong Y, Deavers M et al. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol 2008;46:274-80.
17. Clavel C, Masure M, Putaud I et al. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol 1998;51:737-40.
18. Jeronimo J. Update on the careHPV™ projects. HPV Today 2012;27:9.
19. Day SP, Hudson A, Mast A et al. Analytical performance of the investigational use only Cervista HPV HR test as determined by a multi-center study. J Clin Virol 2009;45(Suppl.):S63-72.
20. Gravitt PE, Peyton CL, Alessi TQ et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
21. Snijders PJF, van den Brule AJC, Schrijnemakers HFJ et al. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1991;71:173-81.
22. Vernon SD, Unger ER, Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol 2000;38:651-5.
23. Cuzick J, Ambroisine L, Cadman L et al. Performance of the Abbott Real Time high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 2010;82:1186-91.
24. Poljak M, Kovanda A, Kocjan BJ et al. The Abbott Real Time High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol Alp Panonica Adriat 2009;18:94-103.
25. Stoler MH, Wright TC Jr, Sharma A et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468-75.
26. Heideman DA, Hesselink AT, Berkhof J et al. Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 2011;49:3983-5.
27. Castle PE, Docktor J, Giachetti C et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007;13:2599-605.
28. Ratnam S, Coutlee F, Fontaine D et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol 2011;49:557-64.
29. Monsonego J, Hudgens MG, Zerat L et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011;129:691-701.
30. Sorbye SW, Fismen S, Gutteberg T et al. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS ONE 2010;5:e12724.
31. Jeantet D, Schwarzmann F, Tromp J et al. NucliSENS EasyQ HPV v1 test - testing for oncogenic activity of human papillomaviruses. J Clin Virol 2009;45(Suppl. 1):S29-37.
32. Jacobs MV, Snijders PJ, van den Brule AJ et al. A general primer GP5+/6+-mediated PCR-enzyme immunoassay for rapid detection of 14 high risk and 6 low risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-5.
33. Coutlee F, Rouleau D, Petignat P et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear Array HPV genotyping test. J Clin Microbiol 2006;44:1998-2006.
34. Kleter B, van Doorn LJ, Schrauwen L et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-17.
35. Schopp B, Holz B, Zago M et al. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the hc2 test. J Med Virol 2010;82:605-15.
36. Pista A, Verdasca N, Oliveira A. Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. J Med Virol 2011;83:272-6.
37. Schmitt M, Bravo IG, Snijders PJ et al. Bead based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504-12.
38. Castle PE, Gutierrez EC, Leitch SV et al. Evaluation of a new DNA test for detection of carcinogenic human papillomavirus. J Clin Microbiol 2011;49:3029-32.
39. Martin CM, O'Leary JJ. Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol 2011;25:605-15.
40. Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
41. Meijer C, Berkhof H, Heideman DAM et al. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;S3:S1-4.
42. Stoler MH, Castle PE, Solomon D et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007;127:335-7.
43. Stevens MP, Garland SM, Rudland E et al. Comparison of the Digene Hybrid Capture 2 assay and Roche Amplicor and Linear Array Human Papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007;45:2130-7.
44. Carozzi F, Bizanzi S, Sani C et al. Agreement between the Amplicor human papillomavirus test and the Hybrid Capture II assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 2007;45:364-9.
45. Poljak M, Ostrbenk A, Seme K et al. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011;49:1721-9.
46. Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008;17:3033-42.
47. Szarewski A, Mesher D, Cadman L et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012;50:1867-73.
48. Cubie HA, Moore C, Waller M et al. The development of a quality assurance programme for HPV testing within the English NHS Cervical Screening LBC/HPV Pilot Study. J Clin Virol 2004;33:287-92.
49. Fagan EJ, Moore C, Jenkins C et al. External quality assessment for molecular detection of human papillomaviruses. J Clin Virol 2010;48:251-4.
50. Tabrizi SN. Quality assessment for human papillomavirus testing. Sex Health 2010;7:335-7.
51. Eklund C, Zhou T, Dillner J, WHO Human Papillomavirus Laboratory Network. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2011;48:4147-55.
52. NHS Cervical Screening Programme. Good practice guide no 3. HPV triage and test of cure: implementation guidance. 2011. Available at: www.csp.nhs.uk/files/F000198_F000196_NHSCSP%20Good%20Practice%20Guide%20no%203%20HPV%20implementation%20guidance.pdf (Accessed 10 February 2013).
53. Arbyn M, Ronco G, Anttila A et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(Suppl. 5):F88-99.
54. NHS Cervical Screening Programme. Achievable Standards, Benchmarks for Reporting, and Criteria for Evaluating Cervical Cytopathology, 3rd edn. 2013. Available at: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp01.pdf.
55. Ortega B. False-negative results found in HPV testing. USA Today 13th January 2013. Available at: http://www.usatoday.com/story/news/nation/2013/01/13/hpv-testing-false-negatives/1830897.
56. Powell N, Smith K, Fiander A. Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J Virol Methods 2006;137:58-62.
57. Horvath CA, Boulet G, Sahebali S et al. Effects of fixation on RNA integrity in a liquid-based cervical cytology setting. J Clin Pathol 2008;61:132-7.
58. Hardie A, Moore C, Patnick J et al. High-risk HPV detection in specimens collected in SurePath preservative fluid: comparison of ambient and refrigerated storage. Cytopathology 2009;20:235-41.
59. Dixon EP, King LM, Adams MD et al. Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTect HPV-Proofer assay. J Virol Methods 2008;154:220-2.
60. Moore C, Cuschieri K, McQueen F et al. Effect of glacial acetic acid pre-treatment of cervical liquid-based cytology specimens on the molecular detection of human papillomavirus. Cytopathology 2013;24:314-20.
61. ® 4800 HPV test. Cytopathology 2013;24:321-6.
62. Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
63. Ronco G, Giorgi-Rossi P, Carozzi F et al. Results at recruitment from a randomised controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501.
64. Naucler P, Ryd W, Tornberg S et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-9.
65. Ogilvie GS, Krajden M, van Niekerk DJ et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial - the HPV FOCAL study. Br J Cancer 2012;107:1917-24.
66. Kitchener HC, Gilham C, Sargent A et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011;47:864-71.
67. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al. Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005;353:2158-68.
68. Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36.
69. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378:1868-73.
70. Castle PE, de Sanjosé S, Qiao YL et al. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 2012;30(Suppl. 5):F117-22.
71. Castle PE, Rodriguez AC, Burk RD et al. Short term persistence and risk of cervical precancer and cancer: population based cohort study. Br Med J 2009;339:b2569.
72. Rijkaart DC, Berkhof J, van Kemenade FJ et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130:602-10.
73. Carozzi F, Gillio-Tos A, Confortini M et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14:168-76.
74. Available at: www.isdscotland.org.
75. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009;339:b2968.
76. de Kok IM, van der Aa MA, van Ballegooijen M et al. Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 2011;128:2174-81.
77. Habbema D, De Kok IM, Brown ML. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q 2012;90:5-37.
78. Moss S, Gray A, Legood R et al. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ 2006;332:83-5.
79. Kelly RS, Patnick J, Kitchener HC et al. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 2011;105:983-8.
80. Moss S, Bailey A, Cubie H et al. Results from the NHSCSP multiple HPV testing study. Presented at the 28th International Papillomavirus Conference, San Juan, Puerto Rico, December 2012. Clinical Science Abstract: pp. 130. Available at: http://www.hpv2012pr.org/HPV2012_PUERTO_RICO_Abstracts%20Clinical_Sciences.pdf.
81. Arbyn M, Roelens J, Cuschieri K et al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer 2013;132:101-8.
82. Sargent A, Bailey A, Turner A et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 2010;48:554-8.
83. Rebolj M, Bonde J, Njor SH et al. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. Br Med J 2011;342:d2757.
84. Keegan H, Pilkington L, O'Brien R et al. Assessing the performance of Cervista HPV test in a routine cervical screening population. Presented at EUROGIN 2012 Congress, Prague, Czech Republic, July 2012. FC 9-8. Available at: http://www.eurogin.com/2012/images/pdf/eurogin-2012-abstracts.pdf.
85. Strander B, Andersson-Ellström A, Milsom I et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007;335:1077.
86. Rebolj M, Helmerhorst T, Habbema D et al. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ 2012;345:e6855.
87. Kocken M, Helmerhorst TJ, Berkhof J et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12:441-50.
88. Canham M, Cuschieri K, Moore C et al. Scottish test of cure study - HPV test comparisons (STOCS-H). Presented at EUROGIN 2012 Congress, Prague, Czech Republic, July 2012. MSS 13-7. Available at: http://www.eurogin.com/2012/images/pdf/eurogin-2012-abstracts.pdf.
89. Bowring J, Albrow R, Fisher A et al. A prospective study of human papillomavirus (HPV) testing to resolve uncertainty in colposcopy. Cytopathology 2013;24:309-13.
90. Scottish HPV Reference Laboratory. Available at: http://www.hps.scot.nhs.uk/reflab/VirLabDetail.aspx?id=26.
91. Forman D, de Martel C, Lacey CJ et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(Suppl. 5):F12-23.
92. Palefsky JM. Practising high-resolution anoscopy. Sex Health 2012;9:580-6.
93. Salit IE, Lytwyn A, Raboud J et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS 2010;24:1307-13.
94. Silling S, Kreuter A, Hellmich M et al. Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men. J Clin Virol 2012;53:325-31.
95. Wentzensen N, Follansbee S, Borgonovo S et al. Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. AIDS 2012;26:2185-92.
96. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
97. Junor E, Kerr G, Oniscu A et al. Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. Br J Cancer 2012;106:358-65.
98. Chaturvedi AK, Engels EA, Pfeiffer RM et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301.
99. Attner P, Du J, Näsman A et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 2010;126:2879-84.
100. Gillison ML, Alemany L, Snijders PJ et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012;30(Suppl. 5):F34-54.
101. Scottish Intercollegiate Guidelines Network: Diagnosis and management of head and neck cancer. 2006. Available at: http://www.sign.ac.uk/pdf/sign90.pdf.
102. Jordan RC, Lingen MW, Perez-Ordonez B et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 2012;36:945-54.
103. Robinson M, Schache A, Sloan P et al. HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol 2012;6(Suppl. 1):S83-90.
104. Smeets SJ, Hesselink AT, Speel EJ et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121:2465-72.
105. Rietbergen MM, Leemans CR, Bloemena E et al. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer 2013;132:1565-71.
106. Weinberger PM, Yu Z, Kountourakis P et al. Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg 2009;141:382-9.
107. Arbyn M, Van Veen EB, Andersson K et al. Cervical cytology biobanking in Europe. Int J Biol Markers 2010;25:117-25.
108. Cuschieri K, Nandwani R, McGough P et al. Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J Med Virol 2011;83:1983-7.
109. Bissett SL, Howell-Jones R, Swift C et al. Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol 2011;83:1744-51.
110. Yi X, Li J, Yu S et al. A new PCR-based mass spectrometry system for high-risk HPV, part I: methods. Am J Clin Pathol 2011;136:913-9.
111. Mollers M, Boot Hein J, Vriend Henrike J et al. Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands. Vaccine 2013;31:394-401.
112. Unger ER, Steinau M, Lin JM et al. Impact of HPV assay on observed population prevalence. Diagn Mol Pathol 2011;20:101-4.
113. Cuschieri K, Kavanagh K, Sinka K et al. Effect of HPV assay choice on perceived prevalence in a population based sample. Diag Molec Pathol 2013;22:85-90.
114. Virtanen A, Nieminen P, Luostarinen T et al. Self-sample HPV tests as an intervention for non-attendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011;9:1960-9.
115. Schmeink CE, Bekkers RL, Massuger LF et al. The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol 2011;21:139-53.
116. Szarewski A, Cadman L, Mesher D et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer 2011;104:915-20.
117. Wikström I, Lindell M, Sanner K et al. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer 2011;105:337-9.
118. Waller J, McCaffery K, Forrest S et al. Acceptability of unsupervised HPV self-sampling using written instructions. J Med Screen 2006;13:208-13.
119. Snijders PJ, Verhoef VM, Arbyn M et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013;132:2223-36.
120. Franco EL, Mahmud SM, Tota J et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009;40:478-85.
121. Almonte M, Sasieni P, Cuzick J. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. Best Pract Res Clin Obstet Gynaecol 2011;25:617-29.
122. Malagon T, Drolet M, Boily MC et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:781-9.
123. Wheeler CM, Castellsagué X, Garland SM. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10.
124. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
125. Choi YH, Chapman R, Gay N et al. Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model. Vaccine 2012;30:3383-8.
126. Durham DP, Poolman EM, Ibuka Y et al. Re-evaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types. J Infect Dis 2012;206:1291-8.
127. von Knebel Doeberitz M, Reuschenbach M, Schmidt D et al. Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics 2012;9:149-63.
128. Tsoumpou I, Arbyn M, Kyrgiou M et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210-20.
129. Schmidt D, Bergeron C, Denton KJ et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011;119:158-66.
130. Denton KJ, Bergeron C, Klement P et al. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol 2010;134:12-21.
131. Zhang Q, Kuhn L, Denny LA et al. Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. Int J Cancer 2007;120:351-6.
132. Roelens J, Reuschenbach M, von Knebel Doeberitz M et al. p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis. Cancer Cytopathol 2012;120:294-307.
133. Wentzensen N, Bergeron C, Cas F et al. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 2007;111:58-66.
134. Gertych A, Joseph AO, Walts AE et al. Automated detection of dual p16/Ki67 nuclear immunoreactivity in liquid-based Pap tests for improved cervical cancer risk stratification. Ann Biomed Eng 2012;40:1192-204.
135. Kruse AJ, Baak JP, Janssen EA et al. Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables. J Pathol 2003;199:462-70.
136. Bergeron C, Schmidt D, Ikenberg H et al. High sensitivity and specificity of p16/Ki-67 dual stained cytology for high grade CIN results from screening and triage trials in over 28, 000 women. Cancer Cytopathol 2010;118(Suppl.):305-6.
137. Pinto AP, Degen M, Villa LL et al. Immunomarkers in gynecologic cytology: the search for the ideal 'biomolecular Papanicolaou test'. Acta Cytol 2012;56:109-21.
138. Henderson D, Hall L, Prpic N et al. The selection and characterization of antibodies to minichromosome maintenance proteins that highlight cervical dysplasia. J Immunol Methods 2011;370:1-13.
139. Depuydt CE, Makar AP, Ruymbeke MJ et al. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiol Biomarkers Prev 2011;20:628-37.
140. Rösl F, Arab A, Klevenz B et al. The effect of DNA methylation on gene regulation of human papillomaviruses. J Gen Virol 1993;74:791-801.
141. Turan T, Kalantari M, Cuschieri K et al. High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia. Virology 2007;361:185-93.
142. Wentzensen N, Sherman ME, Schiffman M et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112:293-9.
143. Clarke MA, Wentzensen N, Mirabello L et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2125-37.
144. Wentzensen N, Sun C, Ghosh A et al. Methylation of HPV18, HPV31, HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012;104:1738-49.